Thiol-ene polymerization with vinylesters and vinylcarbonate

US9814801B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9814801-B2
Application numberUS-201615146951-A
CountryUS
Kind codeB2
Filing dateMay 5, 2016
Priority dateOct 3, 2011
Publication dateNov 14, 2017
Grant dateNov 14, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wherein said one or more vinyl ester monomers and/or vinylcarbonate monomers are respectively selected from compounds of the general formulas (I) and (II) below: wherein n, m R 1 and R 2 have the meaning defined herein; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; and (c) 0 to 10 wt. % of a biocompatible polymerization initiator.

First claim

Opening claim text (preview).

The invention claimed is: 1. A curable composition comprising: (a) 60 wt. % to 95 wt. % of one or more vinylcarbonate monomers, wherein said one or more vinylcarbonate monomers are respectively selected from compounds of the general formula (II) below: wherein m independently ranges from 2 to 1000; R 2 is independently selected from the group consisting of: (i) n-valent radicals, each of said n-valent radicals comprising a carbon chain or a carbon cycle or both, wherein said carbon chain and/or carbon cycle each, independently from one another, comprises from 1 to 30 carbon atoms, wherein said carbon chain can be straight, branched, saturated or unsaturated, and optionally containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and/or wherein said carbon chain optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, wherein said carbon cycle can be saturated or unsaturated, and optionally containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and/or wherein said carbon cycle optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, and (ii) n-valent radicals of biodegradable, biocompatible oligomers and polymers, said oligomers and polymers being selected from the group consisting of polysaccharides, polypeptides, polyamides, polyesters, polycarbonates, polyethers, and fatty acid derivatives; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; (c) 0 to 10 wt. % of a biocompatible polymerization initiator; and (d) a bioactive agent selected from the group consisting of prophylactic agent; antipyretic analgesic anti-inflammatory agent; antibacterial agent; antifungal agent; anti-viral agent; high potency analgesic; cell selective protein; cell adherence promoter; bone formation promoter; porosity forming agent; diagnostic agent or combinations thereof. 2. The curable composition according to claim 1 , wherein at least one vinylcarbonate monomers of the general formula (II), accounts for 50 mole percent of all monomers contained. 3. The curable composition according to claim 1 , wherein at least 50, mole percent of all vinyl carbonate monomers are difunctional, cross linking monomers in which m=3. 4. The curable composition according to claim 1 , wherein said one or more vinylcarbonate monomers are selected from the group consisting of ethylene glycol bis(vinyl carbonate) (EGDVC); 1,4-butanediol bis(vinyl carbonate) (BDDVC); 1,6-hexanediol bis(vinyl carbonate) (HDDVC); glycerine tris(vinyl carbonate) (GTVC); diethylene glycol bis(vinyl carbonate) (DEGDVC); polyethylene glycol (400) bis(vinyl carbonate) (PEGDVC); ricinus oil tris(vinyl carbonate) (RiTVC); hydrated ricinus oil tris(vinyl carbonate) (HRiTVC); and diethylene glycol bis[O—(O′-vinyloxycarbonyl) polylactate] (DEG(PLAVC) 2 ). 5. The curable composition according to claim 1 , wherein R 2 is derived from one or more diols, said one or more diols being selected from the group consisting of: 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, and 1,12-dodecanediol. 6. The curable composition according to claim 1 , wherein R 2 is derived from one or more diols, said one or more diols comprising a polyethylene glycol or a polypropylene glycol. 7. The curable composition of claim 6 , wherein said polyethylene glycol has a molecular weight ranging from 200 g/mole to 1000 g/mole. 8. The curable composition according to claim 1 , wherein said one or more vinyl carbonate monomers are selected from the group consisting of ethylene glycol bis(vinyl carbonate) (EGDVC); 1,4-butanediol bis(vinyl carbonate) (BDDVC); 1,6-hexanediol bis(vinyl carbonate) (HDDVC); glycerine tris(vinyl carbonate) (GTVC); diethylene glycol bis(vinyl carbonate) (DEGDVC); polyethylene glycol(400) bis(vinyl carbonate) (PEGDVC); and ricinus oil tris(vinyl carbonate) (RiTVC). 9. The curable composition according to claim 1 , wherein said one or more multifunctional thiols are selected from the group consisting of: pentaerythritol tetra-(3-mercaptopropionate), ethoxylated pentaerythritol tetra-(3-mercaptopropionate), trimethylpropane tri(3-mercapto-propionate), ethoxylated trimethylpropane tri(3-mercapto-propionate), glycol dimercaptoacetate, trimethylolpropane trimercaptoacetate, polypropylene glycol (3-mercaptopropionate), and polypropylene glycol (3-mercaptopropionate). 10. The curable composition according to claim 1 , wherein said one or more vinyl carbonate monomers are selected from the group consisting of: wherein n is an integer from 1 to 12. 11. The curable composition according to claim 10 , wherein said one or more vinyl carbonate monomers comprise 1,4-Butanediol bis(vinyl carbonate) 12. The curable composition according to claim 1 , wherein said one or more multifunctional thiols are selected from the group consisting of: 13. A method for augmenting or filling a structure in a patient comprising, implanting the curable composition into said patient at a site of the structure; said curable composition comprising: (a) 60 wt. % to 95 wt. % of one or more vinylcarbonate monomers, wherein said one or more vinylcarbonate monomers are respectively selected from compounds of the general formula (II) below: wherein m independently ranges from 2 to 1000; R 2 is independently selected from the group consisting of: (i) n-valent radicals, each of said n-valent radicals comprising a carbon chain or a carbon cycle or both, wherein said carbon chain and/or carbon cycle each, independently from one another, comprises from 1 to 30 carbon atoms, wherein said carbon chain can be straight, branched, saturated or unsaturated, and optionally containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and/or wherein said carbon chain optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, wherein said carbon cycle can be saturated or unsaturated, and optionally containing one or more interspersed heteroatoms, said heteroatoms being selected from the group consisting of oxygen, sulfur and nitrogen, and/or wherein said carbon cycle optionally being substituted with one or more substituents selected from the group consisting of —OH, —COOH, —CN, —CHO, and ═O, and (ii) n-valent radicals of biodegradable, biocompatible oligomers and polymers, said oligomers and polymers being selected from the group consisting of polysaccharides, polypeptides, polyamides, polyesters, polycarbonates, polyethers, and fatty acid derivatives; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; and (c) 0 to 10 wt. % of a biocompatible polymerization initiator; initiating said curable composition to the

Assignees

Inventors

Classifications

  • of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical · CPC title

  • for reconstruction of bones; weight-bearing implants · CPC title

  • Products made by additive manufacturing · CPC title

  • A61L27/16Primary

    obtained by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

  • Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9814801B2 cover?
The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wher…
Who is the assignee on this patent?
Depuy Synthes Products Inc, Univ Wien Tech, Univ Wien Tech
What technology area does this patent fall under?
Primary CPC classification A61L27/16. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).